Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly cardiovascular outcomes in type 2 diabetes (China cohort of EXSCEL)
CTR20150150Phase 3Completed
- Sponsor
- Amylin Pharmaceuticals
- Start
- May 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Amylin Pharmaceuticals. Started May 2015; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20150150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150150.